Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Corporate Update (October 2018)
12 slides from Therapeuticsmd's corporate update, Oct 29, 2018
Slide 1: FDA Approval Conference Call
FDA Approval Conference Call October 29, 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than
Slide 3: TherapeuticsMD, A Premier Women's Health Company
TherapeuticsMD, A Premier Women’s Health Company Annovera™ Annovera™ CONTRACEPTION/ DYSPAREUNIA VASOMOTOR CONTRACEPTION PRENATAL CARE FAMILY PLANNING - (Vulvar & SYMPTOMS PERIMENOPAUSE Vaginal Atrophy) REPRODUCTIVE HEALTH MENOPAUSE MANAGEMENT 3
Slide 4: BIJUVA Key Clinical Attributes
BIJUVA is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause Key Clinical Attributes ▪ First and only bio-identical* combination of estradiol to reduce moderate to severe hot flashes combined with progesterone to help reduce the risk to the
Slide 5: BIJUVA Product Development Rationale
BIJUVA Product Development Rationale ▪ 2002 Post Women’s Health Initiative, women and healthcare providers shifted to compounded bio-identical hormone therapy containing estradiol and progesterone as an alternative despite being unapproved drugs that are not covered by insurance ― Over 90M+ scripts
Slide 6: BIJUVA Fulfills the Therapeutic Gap For Stakeholders
BIJUVA Fulfills the Therapeutic Gap For Stakeholders Patients ▪ Meets demand for bio-identical hormone therapy with a FDA approved product with established safety and efficacy profile ▪ One prescription, one copay, one pill daily reduces out-of-pocket costs via insurance coverage ▪ Eliminates the ri
Slide 7: BIJUVA Substitutable Market
BIJUVA Substitutable Market Column 1 Column 2 Column 3 FDA-Approved Off Label Combination Synthetic Compounded Combination Separate Bio-Identical E+P1 Bio-Identical E+P BIJUVA E & P Pills Substitutable Market TRx US: ~3.8 million1 ~3 million2 12 – 18 million3 BIJUVA Potential $760M-$950M4 $600M-$750
Slide 8: BIO-IGNITE Compounding Pharmacy Partnership Strategy
BIO-IGNITETM Compounding Pharmacy Partnership Strategy BIO-IGNITETM started as an outreach program to quantify the number of compounded bio-identical estradiol and progesterone prescriptions currently dispensed by the 3,000 high-volume compounding pharmacies, and qualify their interests in distribut
Slide 9: TherapeuticsMD, A Premier Women's Health Company
TherapeuticsMD, A Premier Women’s Health Company Annovera™ Annovera™ CONTRACEPTION/ DYSPAREUNIA VASOMOTOR CONTRACEPTION PRENATAL CARE FAMILY PLANNING - (Vulvar & SYMPTOMS PERIMENOPAUSE Vaginal Atrophy) REPRODUCTIVE HEALTH MENOPAUSE MANAGEMENT 9
Slide 10: Executing Our Strategy
Executing Our Strategy ▪ Track record of successful execution with 3 products approved by the FDA since May of this year for ~ $500 million in equity ▪ Developed two products, IMVEXXY and BIJUVA, from Phase 1 through approval ▪ Licensed-in 1 New Chemical Entity - ANNOVERA ▪ Primary focus now on comm
Slide 11: Questions
QUESTIONS ANSWERS _ TherapeuticsMD’ 7 For Her. For Life. j
Slide 12: Thank You!
TherapeuticsMD THANK YOU! TherapeuticsMD” For Her. For Life. = 7, 12